Microban has long been a trusted partner in a wide range of sectors – from consumer and healthcare to industrial and construction – and this announcement adds to the versatility of the company’s technology portfolio.
Thorough testing was performed to evaluate the efficacy of each product type against many viruses, including bacteriophage Phi6, an important surrogate virus for SARS-CoV-2.
The results showed that articles treated with these technologies can now benefit from reduced viral loading by up to 99%. Antiviral technologies from Microban inhibit the viruses’ ability to remain viable on surfaces.
Michael Ruby, president of Microban International, said: “We are excited with the latest results confirming the antiviral activity of our new technologies. Assessing antiviral efficacy in treated products to a standard that meets the complex regulatory landscape is an arduous process, but we have been confident throughout that our innovative solutions conformed to the rigorous ISO standards.
“Our world-class research team and global in-house regulatory department worked diligently to ensure that the technology is recognised as effective and compliant across various markets, to support partners with their claims and give customers even greater confidence in products protected with Microban antiviral technology.”